Securities maintained its Neutral rating on Revance Therapeutics (NASDAQ:RVNC) with a steady price target of $3.65, closely ...

The Scottish government’s hunt for a financial adviser for the nation’s debut bond sale is proving more costly than ...

Barclays Bank PLC (the “Issuer”) announced today that, in connection with its previously announced cash tender offers (each, ...